Paper Details

  1. Home
  2. Paper Details

Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome.

Author: ChangF Y, ChangS S, ChenC Y, KangL J, LeeS D, LuC L, LuR H

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Irritable bowel syndrome (IBS) is a disorder affecting the colon. Pinaverlum bromide and mebeverine are medications that have been shown to be effective in treating IBS for a longer period of time (12-16 weeks). This study investigates the effectiveness of these medications for short-term treatment of IBS and their impact on bowel movement speed. The study will also explore if these medications work by influencing specific chemicals in the gut (substance P and neuropeptide Y) that affect bowel movement.
Paper Details　
Original Abstract of the Article :
Irritable bowel syndrome (IBS) is a colonic function disorder. Both pinaverlum bromide (a selective calcium channel blocker) and mebeverine (an antispasmodic) are reported to be effective in the long-term (12-16 weeks) treatment of IBS patients. Their efficacy in the short-term treatment of IBS pati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1440-1746.2000.02230.x

データ提供：米国国立医学図書館（NLM）

Exploring the Gut's Secret Language: Understanding Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a complex digestive disorder that affects millions. This research explores the potential of two medications, pinaverlum bromide and mebeverine, to ease the symptoms of IBS. It's like deciphering the whispers of the desert wind to understand the delicate balance of the digestive system.

The study delves into the efficacy of these medications for short-term treatment and their impact on colonic transit time. It also investigates the role of substance P and neuropeptide Y, neurotransmitters that influence gut motility, in the effectiveness of these medications. This research is like meticulously examining the tracks left by a desert creature to understand its movements and behavior.

The findings suggest that while these medications have shown promise in long-term treatment, their short-term efficacy and their exact mechanisms of action remain unclear. Further research is needed to uncover the full story of how these medications interact with the gut's complex communication system.

Unveiling the Gut's Mysteries

This research highlights the need for further exploration to better understand IBS and its treatment. Much like a vast desert still holds secrets, the intricacies of the digestive system require continued investigation. The findings suggest that exploring the interaction between medications and neurotransmitters could offer valuable insights into the treatment of IBS.

Mind Your Gut

While the study doesn't provide definitive answers, it emphasizes the importance of carefully considering all treatment options for IBS. Just as a traveler in the desert needs to be mindful of the terrain, it's crucial to understand the potential benefits and risks of different medications. Working closely with a healthcare professional to find the most effective and safe approach is key to navigating the challenges of IBS.

Dr.Camel's Conclusion

This research serves as a reminder that the journey to understanding IBS is ongoing. The desert of digestive disorders holds many mysteries, and we must continue to explore its complexities to find solutions that bring comfort and well-being.

Date :
  1. Date Completed 2001-02-08
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

11022835

DOI: Digital Object Identifier

10.1046/j.1440-1746.2000.02230.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.